10-Q: Nuo Therapeutics Q3 Revenue Soars, Going Concern Doubts Persist

Sentiment:

Quarterly Report 30 October 2025 4:31 PM

Nuo Therapeutics reported a significant increase in Q3 2025 revenue driven by product sales and a new distribution agreement with Smith+Nephew, yet continues to face substantial doubt about its ability to continue as a going concern.

Capital raiseThe company explicitly states that current resources and projected revenue are insufficient for the next 12 months, indicating a need for additional capital.The company has an effective S-3 shelf registration statement enabling it to offer and sell up to $15 million in common stock from time to time.The company sold 527,612 shares of common stock in a private placement in July 2025 for proceeds of $791,418.The company received $113,541 from the exercise of common stock options during the three-month period ended September 30, 2025.The company warns that any equity financing may cause further substantial dilution to stockholders and could involve the issuance of securities with rights senior to common stock.Any debt financing may require compliance with additional onerous financial covenants and restrict business operations.

Better than expectedTotal revenue for the three months ended September 30, 2025, increased significantly to $1,032,096 from $370,951 in the prior year.Total revenue for the nine months ended September 30, 2025, increased significantly to $2,216,679 from $970,301 in the prior year.Net cash used in operating activities for the nine months ended September 30, 2025, improved substantially to $(442,325) from $(1,741,083) in the prior year.The company secured a major distribution agreement with Smith+Nephew, including a $1.5 million upfront fee, which contributed to the revenue increase and improved cash position.

Summary

Total revenue for the three months ended September 30, 2025, increased to $1,032,096, up from $370,951 in the prior year, including $75,000 in distribution fee revenue.
Nine-month total revenue reached $2,216,679, a substantial increase from $970,301 in the same period last year, with $150,000 from the Smith+Nephew distribution agreement.
Gross profit for the three months was $625,375 (61% margin) and for nine months was $1,529,587 (69% margin), both up year-over-year but with declining margins due to low-margin centrifuge device sales.
Net loss for the three months improved to $(537,919) from $(578,167), but for the nine months, it worsened to $(1,933,736) from $(1,827,039).
The company reported an accumulated deficit of approximately $34.2 million and a stockholders' deficit of approximately $0.4 million as of September 30, 2025.
Cash on hand was $514,797 at September 30, 2025, an increase from $283,714 at December 31, 2024.
A $1.5 million upfront distribution fee was received from Smith+Nephew, with $150,000 recognized as revenue during the nine months ended September 30, 2025.
The company's disclosure controls and procedures were deemed not effective due to insufficient accounting and financial reporting resources, a material weakness.

Sentiment

Score: 4

Explanation: While revenue growth and a major distribution deal are positive, the persistent 'going concern' doubt, accumulated deficit, declining gross margins, and ineffective internal controls present significant challenges and risks, tempering overall sentiment.

Positives

Significant revenue growth: Total revenue for Q3 2025 increased 178% to $1,032,096, and nine-month revenue increased 128% to $2,216,679 year-over-year.
New distribution agreement: Secured a 5-year exclusive distribution agreement with Smith+Nephew for a private label Aurix product, including a $1.5 million upfront fee and potential $750,000 in milestone fees.
Improved operating cash flow: Net cash used in operating activities for the nine months ended September 30, 2025, significantly improved to $(442,325) from $(1,741,083) in the prior year.
Increased cash balance: Cash on hand increased to $514,797 as of September 30, 2025, from $283,714 at December 31, 2024.
Expanding customer base: Aurix product revenues increased due to an expanding customer base and a growing sales agent network of over 200 representatives.
Favorable CMS reimbursement: National coverage determination for autologous PRP for diabetic wounds and economically viable payment rates for physician offices ($890 per treatment) effective January 1, 2025.
Dual sourcing for a key component: Established dual supply for the ascorbic acid reagent component, reducing reliance on a single supplier.

Negatives

Going concern doubt: Substantial doubt exists about the ability to continue as a going concern, with current resources and projected revenue insufficient for the next 12 months.
Accumulated deficit and stockholders' deficit: Accumulated deficit grew to $34.2 million, and the company moved into a stockholders' deficit of $(419,606) as of September 30, 2025.
Worsening nine-month net loss: Net loss for the nine months ended September 30, 2025, increased to $(1,933,736) from $(1,827,039) in the prior year.
Declining gross margins: Aggregate gross margin decreased to 61% in Q3 2025 (from 73%) and 69% for the nine months (from 78%), primarily due to low-margin centrifuge device sales to Smith+Nephew.
Increased operating expenses: Total operating expenses rose by $884,000 for the nine months, driven by higher professional fees, third-party commissions, and compensation costs.
Ineffective disclosure controls: Disclosure controls and procedures were deemed not effective due to material weaknesses related to insufficient accounting and financial reporting resources.
Forfeited warrants: Performance goals for 250,000 stock purchase warrants were not met, leading to their cancellation and forfeiture.

Risks

Limited revenue base and sources of working capital.
Limited operating experience.
Ability to continue as a going concern.
Dilutive impact of raising additional equity or debt.
Ability to timely and accurately report financial results and prevent fraud if unable to maintain effective disclosure and internal controls.
Acceptance of Aurix product by the medical community and patients.
Ability to obtain adequate reimbursement from third-party payors.
Ability to contract with healthcare providers.
Reliance on several single-source suppliers (e.g., bovine thrombin from Pfizer) and ability to source raw materials at affordable costs.
Ability to protect intellectual property.
Compliance with governmental regulations.
Ability to successfully sell and market the Aurix System.
Ability to perform under and realize sales and related benefits from the distribution agreement with Smith+Nephew, as well as Smith+Nephew's ability to market and sell its private label Aurix product.
Fees, minimum purchase commitments, expenses, and costs associated with the distribution agreement with Smith+Nephew.
Impact of and ability to undertake any license of Aurix product, or receive and negotiate a business combination offer, due to binding notification and negotiation rights provided to Smith+Nephew.
Ability to successfully pursue strategic collaborations to help develop, support, or commercialize current and future products.

Future Outlook

The company anticipates continued revenue growth for its Aurix product, driven by an expanding customer base and sales agent network. Modest sales are expected from the Smith+Nephew private label distribution agreement in the next 12 months, with associated expenses also increasing. The company believes its current resources and projected revenue are insufficient for the next 12 months and will require additional external capital to fund operations.

Management Comments

"We believe based on the operating cash requirements and capital expenditures expected for the next twelve months that our current resources and projected revenue from sales of Aurix products are insufficient to support our operations for the next 12 months from the date these financial statements are issued."
"We believe that Smith+Nephew will need time to establish and begin commercial sales of its Private Label product. As a result, we anticipate modest sales under the Distribution Agreement during the next 12 months."
"Management believes that the consolidated financial statements and related financial information included in this Quarterly Report fairly present in all material respects our financial condition, results of operations and cash flows as of the dates presented, and for the periods ended on such dates, in conformity with GAAP."

Industry Context

The company operates in the advanced wound care market, estimated at $10.8 billion globally in 2021 and $4.15 billion in North America in 2020. The market is driven by an aging population and increasing prevalence of diabetes, leading to a growing patient population with chronic, non-healing wounds. The Aurix System, a point-of-care PRP therapy, competes within this market, benefiting from a favorable CMS National Coverage Determination for diabetic wounds and economically viable reimbursement rates in physician offices. The distribution agreement with Smith+Nephew, a global medical technology company, positions Nuo to potentially expand its market reach significantly.

Comparison to Industry Standards

The advanced wound care market is estimated at approximately $10.8 billion globally in 2021, with the North American market at approximately $4.15 billion in 2020. Nuo's total revenue of $2.2 million for the nine months ended September 30, 2025, indicates a very small market share within this large industry.
The cost of treating diabetic foot ulcers in the U.S. alone is estimated at $9-$13 billion annually, highlighting a significant unmet medical need that Aurix aims to address.
Aurix is one of only three platelet-derived products cleared by the FDA for chronic wound care use, suggesting a relatively specialized and less crowded segment within the broader wound care device market.
The CMS national average reimbursement rate for the Aurix System is $1,829 per treatment in hospital outpatient departments and $890 in physician offices, which are specific benchmarks for product usage and economic viability within the U.S. healthcare system.
The distribution agreement with Smith+Nephew, a global medical technology company, suggests a validation of Aurix's potential, as such partnerships are common for smaller companies seeking to leverage larger players' distribution networks.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Internal Control Weakness	Disclosure controls and procedures were not effective due to insufficient accounting and financial reporting resources, preventing the company from maintaining appropriately designed and monitored internal control over financial reporting.	September 30, 2025	Raises risk of material misstatement in financial statements not being prevented or detected on a timely basis, though management believes current statements are fairly presented.
Board Oversight	Management, under the oversight of the Audit Committee of the Board of Directors, will continue to implement measures to improve internal control over financial reporting.	Ongoing	Indicates active efforts to address control deficiencies, but remediation requires sustained validation and testing.

Related Party Transactions

Certain related parties, including a principal shareholder and a member of the Board of Directors, invested an aggregate of $205,919 in the July 2025 private placement transaction.

Stakeholder Impact

Shareholders: Potential for significant dilution from future equity financings due to the company's need for additional capital and its S-3 shelf registration. Existing shareholders face a stockholders' deficit.
Customers (Healthcare Providers): Continued access to Aurix System for wound care, potentially through Smith+Nephew's private label or Nuo's branded product. Improved reimbursement clarity for diabetic wounds.
Employees: Added sales management personnel, but overall financial instability and going concern doubt could create uncertainty.
Suppliers: Continued reliance on single-source suppliers for critical components (e.g., Pfizer for bovine thrombin) poses a risk to supply chain stability.
Smith+Nephew: Benefits from exclusive distribution rights for a private label Aurix product in the US, with minimum purchase commitments and potential milestone fees. Also holds notification and first negotiation rights for future Aurix licenses or business combinations.

Next Steps

Continue engaging and establishing relationships with providers treating chronic non-healing wounds to demonstrate clinical benefits of Aurix.
Expand distributor and sales agent arrangements throughout the United States and internationally.
Establish commercial customer relationships with wound care providers, primarily in hospital outpatient wound care clinics.
Ensure reimbursement mechanisms are appropriately administered by local Medicare Administrative Contractors.
Smith+Nephew to establish and begin commercial sales of its Private Label product.
Management will continue assessing the need for hiring additional internal accounting and third-party financial reporting resources.
Management will continue to implement measures designed to improve internal control over financial reporting to remediate identified material weaknesses.
Potentially utilize the S-3 shelf registration statement to raise additional capital.

Key Dates

Date	Description
1998	Nuo Therapeutics, Inc. organized as Informatix Holdings, Inc.
1999	Autologous Wound Therapy, Inc. merged with Informatix Holdings, Inc., name changed to Autologous Wound Therapy, Inc.
2000	Autologous Wound Therapy, Inc. changed name to Cytomedix, Inc.
2001	Cytomedix, Inc. filed for bankruptcy.
2002	Cytomedix, Inc. emerged from bankruptcy.
September 2007	Cytomedix received Section 510(k) clearance from FDA for the AutoloGel System (now Aurix System) for wound management.
2012	Cytomedix acquired Aldagen, Inc.; Medicare National Coverage Determination (NCD) reversed non-coverage for autologous blood derived products in wound care, allowing coverage under CED program.
2014	Cytomedix changed its name to Nuo Therapeutics, Inc.
2016	Nuo filed for and emerged from bankruptcy under Chapter 11 Plan of Reorganization; Board of Directors approved 2016 Omnibus Incentive Plan.
May 1, 2019	Nuo furloughed remaining employees and ceased standard operational activities awaiting CMS reconsideration request.
May 8, 2019	Formal public request for reconsideration submitted to CMS Coverage and Analysis Group (CAG).
April 2021	CMS issued a favorable National Coverage Determination (NCD) for autologous PRP products, mandating national reimbursement coverage for Aurix in chronic non-healing diabetic wounds.
October 2021	Nuo restarted business activities.
February 2022	Entered into a commercial operating lease for primary office and warehouse/distribution space in Texas.
May 2022	Commercially available Aurix product first available for demonstration and evaluation purposes.
August 24, 2022	Entered into Common Stock and Warrant Purchase Agreement with Pacific Medical, Inc.
December 31, 2022	Issued two sales incentive warrants to a distribution partner.
December 31, 2023	Expiration of Pacific Med's Participation Rights; 2024 Financing Participation warrant issued on January 1, 2024.
January 1, 2024	2024 Financing Participation warrant issued to Pacific Med with an exercise price of $0.56 per share.
June 2024	Received $151,200 from the exercise of 270,000 warrants by Pacific Med.
May and September 2024	Sold 2,000,000 shares of common stock in two private placements for total proceeds of $1,500,000.
November 2024	CMS issued final Physician Fee Schedule (PFS) for calendar 2025, establishing a national average payment of $890 for Aurix in physician offices.
January 1, 2025	Aurix System became economically viable within the physician office care setting due to new CMS PFS.
January 15, 2025	Final determination date for 250,000 sales incentive warrants, leading to their cancellation and forfeiture.
March 31, 2025	Entered into a Distribution Agreement with Smith & Nephew, Inc.
May 12, 2025	SEC declared the company's shelf registration statement on Form S-3 effective, enabling offering of up to $15 million in common stock.
May 14, 2025	Entered into Amendment No. 1 to the Distribution Agreement with Smith+Nephew, providing for an interim sales agency arrangement.
July 2025	Sold 527,612 shares of common stock in a private placement for proceeds of $791,418.
July 30, 2025	Closing date for the private placement of 527,612 shares of common stock.
September 30, 2025	End of the quarterly reporting period.
October 29, 2025	Number of shares outstanding of common stock was 48,077,745.
October 30, 2025	Date of filing of the 10-Q report.
December 31, 2025	Interim sales agency arrangement with Smith+Nephew terminates by this date.
March 2027	Expiration of the primary office and warehouse/distribution space lease.
December 31, 2027	Expiration date for the first 2022 sales incentive warrant (now forfeited).
December 31, 2028	Expiration date for the second 2022 sales incentive warrant.

Recommendation

hold

While Nuo Therapeutics shows promising revenue growth and a significant distribution agreement with Smith+Nephew, the persistent "going concern" doubt, accumulated deficit, and material weaknesses in internal controls present substantial risks. The company's need for further capital raises the specter of significant dilution. The positive operational momentum is offset by these fundamental financial and governance challenges, making it a speculative investment. A "hold" recommendation is appropriate for existing investors to monitor the execution of the Smith+Nephew agreement and the company's ability to address its liquidity and internal control issues. New investors should exercise extreme caution due to the high risk profile.

Keywords

Nuo Therapeutics, Aurix System, Wound Care, Medical Device, Platelet Rich Plasma, PRP, SEC Filing, 10-Q, Financial Results, Smith+Nephew, Distribution Agreement, Going Concern, Healthcare, Biologics, Diabetic Foot Ulcers, CMS Reimbursement, Stockholders Deficit, Revenue Growth, Operating Loss

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.